FDA Premarket Cybersecurity Guidance for Medical Device Operating Systems: What FDA Recommends for Submissions

Most OEMs hear “FDA cybersecurity” and think SBOM. That is one element. It is not the full picture.
The broader framework is FDA’s Premarket Cybersecurity Guidance – Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions – which describes FDA’s current thinking on device cybersecurity design, labeling, and the medical device cybersecurity documentation FDA recommends for premarket submissions. It covers devices with cybersecurity risk, not just network-connected devices.
Section 524B of the FD&C Act is the binding statute that gives FDA authority to require cybersecurity information for “cyber devices.” But 524B is the legal floor, not the complete cybersecurity documentation model. The Guidance describes the broader evidence package manufacturers should prepare – and it goes well beyond an SBOM.
This matters for OS selection because the operating system carries a significant part of the software attack surface. But the OS is not the whole device. The OS vendor’s job is to provide structured technical evidence at the platform layer. The OEM owns the device-level submission, risk management, validation, and postmarket obligations.

What FDA Recommends in Premarket Submissions

FDA issued the current final guidance on February 3, 2026, superseding the June 27, 2025 version. It aligns terminology with the Quality Management System Regulation (QMSR), which became effective on February 2, 2026 and incorporates ISO 13485:2016 by reference into 21 CFR Part 820.
FDA recommends that manufacturers address cybersecurity as part of device safety and quality management. The guidance identifies a Secure Product Development Framework (SPDF) as one recommended approach to manage cybersecurity risks throughout the product lifecycle. Common threat modeling approaches include STRIDE, attack trees, and MITRE-informed methodologies.
For a premarket submission, FDA generally recommends:

Submission Element	What FDA Recommends
SPDF	Evidence that cybersecurity is addressed within the QMS. FDA identifies SPDF as one recommended approach
Threat Model	Device-specific threat model with methodology rationale, identified risks, mitigations, and residual risk analysis
Security Architecture	Architecture diagrams, data flow diagrams, trust boundaries, and interface inventory
SBOM	Inventory of all software components with version information. Section 524B requires this for cyber devices
Security Testing	Cybersecurity testing, which may include penetration testing, static/dynamic analysis, fuzz testing, and attack surface analysis
CVD Process	Documented process for receiving, evaluating, and communicating vulnerability disclosures
Postmarket Plan	Process for monitoring vulnerabilities, deploying patches, and communicating with FDA
Cybersecurity Labeling	Security features and procedures documented for end users and healthcare facilities

No single tool or vendor covers all of this. Different elements are handled by different parts of the organization.

524B vs. the Full Guidance

Section 524B applies to “cyber devices” – generally a device that includes sponsor-validated software, connects to the internet, and contains technological characteristics vulnerable to cybersecurity threats. When classification is unclear, manufacturers should seek regulatory advice.

	Section 524B	FDA Premarket Cybersecurity Guidance
What it is	Binding statute	FDA guidance (current thinking, generally not binding on its own)
Scope	Cyber devices only	Devices with cybersecurity risk, including certain non-connected software devices
Coverage	Vulnerability management, updates/patches, SBOM, coordinated disclosure	SPDF, threat model, security architecture, testing, SBOM, CVD, postmarket plan, labeling
Enforcement	FDA may refuse to accept certain submissions lacking required cybersecurity information	FDA recommends this framework for consistent review, scaled to risk

The Guidance describes cybersecurity recommendations for devices with cybersecurity risk, not only internet-connected cyber devices. If your device contains software and has cybersecurity risk, FDA recommends addressing cybersecurity in your submission – connected or not. SBOM alone is not enough. (For EU-market devices, see also CRA Medical Device Compliance: What’s Really Exempt?)

What Changed in February 2026: Why OS-Layer Evidence Matters More

FDA’s February 2026 guidance update aligned terminology with QMSR. For OEMs, the practical point is not that the OS vendor becomes responsible for the quality system. The OEM remains responsible for regulatory submissions, QMS implementation, cybersecurity risk management, validation, and postmarket obligations.
The OS vendor’s role is narrower but important: providing structured technical evidence that the OEM can integrate into its own documentation. FDA’s guidance states that known vulnerabilities should be assessed as reasonably foreseeable risks as part of cybersecurity risk management. FDA’s updated inspection program uses a risk-based approach. Premarket cybersecurity documentation is receiving close attention. FDA’s guidance states that inadequate cybersecurity information may affect review, and Section 524B creates binding submission requirements for cyber devices. For OEMs, the practical point is simple: OS-layer artifacts should be structured, traceable, and usable in the device-level evidence package.
For a medical device operating system, structured OS-layer evidence includes:

• SBOM artifacts for OS platform components
• Vulnerability monitoring and triage records
• Patch availability and update records
• Secure boot documentation
• Secure update mechanism documentation
• OS-level security architecture inputs

That is where a medical-grade OS platform should differ from a general-purpose Linux baseline: not by claiming regulatory compliance by itself, but by producing traceable, review-ready OS-layer artifacts that the OEM can integrate into its device-level risk management, verification, validation, and postmarket processes.

What MediTUX OS Covers at the Platform Layer

SBOM Generation. MediTUX OS is designed to generate build-time SBOM artifacts for OS platform components included in the build – kernel, userspace, libraries, and supported firmware components where available. For an embedded Linux distribution, this can represent hundreds of kernel, userspace, library, runtime, and firmware-related components, depending on the selected image profile and hardware platform. OEMs remain responsible for application-layer, device-specific, and cloud components in the complete device SBOM.
Vulnerability Monitoring. L4B operates MOON (MediTUX OS Operations Network), designed to support OS-layer vulnerability monitoring, triage, patch availability tracking, and update support for MediTUX OS components. Under QMSR and FDA’s cybersecurity guidance, these monitoring outputs can support the OEM’s quality system processes because known vulnerabilities should be assessed as reasonably foreseeable risks. OEMs remain responsible for device-level evaluation, safety impact assessment, and deployment decisions. A CVE match is not automatically a device safety issue. The OEM still needs exploitability analysis in the device context: whether the vulnerable component is included, whether the affected code path is reachable, whether compensating controls exist, and whether exploitation could affect safety, effectiveness, or data integrity.
Secure Boot. MediTUX OS is designed to support secure boot workflows for supported hardware platforms, including cryptographic integrity checks at boot stages, subject to the target hardware and system architecture.
Secure Updates. MediTUX OS includes sFOTA (secure Firmware Over The Air), designed to support secure software update workflows, including cryptographic integrity checks and rollback-oriented update strategies, subject to the target hardware, system architecture, and customer implementation.

What the OEM Must Handle Separately

The OS handles the platform layer. The rest requires device-level expertise.

Element	Who Handles It
OS-layer SBOM, CVE monitoring, secure boot, OTA	OS platform vendor (MediTUX OS, MOON, sFOTA)
Device-level threat model	OEM or cybersecurity consultancy
Penetration testing	OEM or independent testing firm
CVD process	OEM (manufacturer obligation)
Complete security architecture	OEM, with OS platform inputs
Cybersecurity labeling	OEM
SPDF integration into QMS	OEM, with OS platform support for OS-layer processes
Postmarket surveillance plan	OEM, with OS platform support for OS-layer monitoring

That boundary matters. A credible OS vendor should make the platform layer easier to document, not pretend to own the full submission.

Why General-Purpose Linux Makes This Harder

OEMs using Ubuntu, Debian, or Yocto-built distributions face the same device-level work – threat modeling, pen testing, CVD – but they also carry the full OS-layer burden. (For a deeper look at why, see Why General-Purpose Linux Isn’t Enough for Medical Devices.)

• SBOM generation requires custom tooling
• CVE monitoring across hundreds of packages is a permanent commitment
• Secure boot must be built and validated
• OTA infrastructure must be developed and maintained
• OS-level security architecture documentation starts from scratch
• Long-term kernel and package maintenance (10+ years) is on the OEM
• Under QMSR, relevant OS-layer cybersecurity processes should be integrated into auditable quality system documentation where they affect device safety, design controls, risk management, or postmarket surveillance

That is the point of a medical-grade OS platform: reduce the OS-layer burden so the OEM team can focus on the device-specific risks only they can assess.

FAQ

Does the FDA require a specific OS cybersecurity standard? No. FDA does not mandate a specific cybersecurity standard for the operating system itself. The Guidance references IEC 81001-5-1 as a recognized consensus standard, but the submission still needs to show how cybersecurity risk is managed for the actual device.
Is Section 524B the main cybersecurity requirement? It is the binding statute for cyber devices. But it is not the whole picture. The broader framework FDA recommends is the Premarket Cybersecurity Guidance, which covers devices with cybersecurity risk – including devices that are not network-connected.
Does MediTUX OS handle all FDA cybersecurity requirements? No, and no OS platform can. MediTUX OS supports the OS platform layer: SBOM generation, vulnerability monitoring through MOON, secure boot for supported hardware, and secure updates through sFOTA. Threat modeling, penetration testing, CVD, security architecture, and labeling require device-level expertise that the OEM provides directly or through a specialized partner. (See also: Ensuring Medical Device Security with MediTUX OS.)
What is SPDF? Secure Product Development Framework. FDA identifies it as one recommended way to manage cybersecurity risks across the product lifecycle. The idea is that cybersecurity is built into the development process from the start, not bolted on before submission.
How does QMSR affect cybersecurity? QMSR means that cybersecurity-related activities affecting device safety should be part of the quality management system, not treated as a separate exercise. FDA’s guidance states that known vulnerabilities should be assessed as reasonably foreseeable risks. For OEMs, this means OS-layer artifacts like SBOMs, vulnerability records, and update logs should be organized so they fit into the QMS, not left in an engineering repository disconnected from quality-system processes.
Does MediTUX OS generate SBOM artifacts for FDA premarket submissions? Yes, at the OS platform layer. MediTUX OS is designed to generate build-time SBOM artifacts for the OS components included in the build. The complete device SBOM – including application-level, cloud, and other non-OS components – remains the OEM’s responsibility.

---

---

Disclaimer: This content is for general informational and marketing purposes only and does not constitute legal, regulatory, cybersecurity, clinical, or quality-system advice. FDA guidance generally reflects FDA’s current thinking and is not binding unless tied to statutory or regulatory requirements. Medical device manufacturers remain responsible for determining applicable requirements, implementing their QMS, managing device-level cybersecurity risk, preparing submissions, and meeting postmarket obligations. MediTUX OS, MOON, and sFOTA support OS-layer cybersecurity activities but do not replace the manufacturer’s device-level responsibilities.